The management of ulcerative colitis.
The treatment of ulcerative colitis (UC) remains empiric because of undetermined etiology and pathogenesis and incomplete understanding of the underlying immunoinflammatory events. However, considerable progress has been made in the management of this disease with the availability and wider use of newer aminosalicylates and immunomodulating agents. The clinician confronted with a patient with chronic ulcerative colitis must weigh the advantages of continued medical therapy against the potential curability with improved surgical techniques. After a brief discussion of the current classes of medicines and their pathophysiological basis of action, we focus on standard approaches to the different clinical syndromes and their complications.
Hanauer
S B
SB
Department of Medicine, University of Chicago Medical Center, Illinois 60637, USA.
Baert
F J
FJ
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D011247:Pregnancy; D012459:Salicylates / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D012459:Salicylates